pipeline
Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment
Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline
Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor
Inventiva, layoffs, pipeline reduction, lanifibranor, MASH, Phase 3 trial, biotech restructuring
Bristol Myers Squibb Expands Cost-Cutting Measures and Streamlines Pipeline for Future Growth
Bristol Myers Squibb, cost-cutting, pipeline optimization, patent cliff, strategic restructuring, operational efficiency, pharmaceutical industry
I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig
I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers
Adcendo Secures $135M for ADC Pipeline Development
Adcendo, ADC pipeline, funding, biotech, cancer treatment, clinical trials
Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline
Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate
Novartis Enhances Mid-Term Growth Projections Following Strategic Transformation
Novartis, mid-term guidance, growth projections, pharmaceutical industry, innovative medicines, pipeline development
Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts
Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program
Scholar Rock Seeks $275M Funding Following Successful SMA Therapy Trial
Scholar Rock, funding, SMA therapy, clinical trial, Vincerx, pipeline reshuffle
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration